Mohammed A. Hassan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammed A. Hassan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Abdulrahman L. Al‑Malki
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia
1 shared publication- Abeer M. Bin Thalab
Department of Pathology, College of Medicine, Hadhramout University, Mukalla 50511, Yemen
1 shared publication - Abudukadeer Kuerban
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
1 shared publication - Asaad Kayali
Department of Biomedical Sciences, College of Health Science, Abu Dhabi University, Abu Dhabi P.O. Box 59911, United Arab Emirates
1 shared publication - Asrar S. Sayad
Department of Obstetrics and Gynecology, College of Medicine, Hadhramout University, Mukalla 50511, Yemen
1 shared publication - Aulia Risqi Fatmariza
Faculty of Health Technology and Management, Institut Ilmu Kesehatan Bhakti Wiyata Kediri, East Java, Indonesia
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
Ficus carica as an Antidiabetic Agent: Evidence from a Meta-analysis of In Vivo Studies
Recent evidence indicates that Ficus carica may exert glucose-lowering effects under diabetic conditions. However, reductions generally do not restore blood glucose to normal levels, raising questions about its reliability as an antidiabetic agent. This study aimed to systematically evaluate the glucose-lowering effects of F. carica in experimental diabetes models through meta-analysis, with additional assessments of dosage influence and comparison to glibenclamide. Relevant studies were retrieved from PubMed, Scopus, and Web of Science, including in vivo experiments on diabetic rats reporting blood glucose or insulin outcomes after F. carica intervention. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using meta-analysis based on leaf extract, dosage, and comparator treatment. F. carica leaf extract significantly reduced blood glucose compared to diabetic controls (SMD = –5.92; 95% CI [–8.13, –3.72]; p = .00001). Subgroup analyses demonstrated consistent effects at doses below 500 mg/kg BW (SMD = –8.11; 95% CI [–12.83, –3.39]; p = .0008) and above 400 mg/kg BW (SMD = –4.95; 95% CI [–7.49, –2.40]; p < .0001). Leaf extract showed no superior effect compared to glibenclamide (SMD = 2.10; 95% CI [0.91, 3.29]; p = .0006). A significant effect on insulin levels was observed in leaf extract (SMD = –3.65; 95% CI [–7.12, –0.18]; p = .04), though inconsistent effects were noted across other plant parts. In conclusion, F. carica demonstrates antidiabetic potential by reducing blood glucose in diabetic rats, but effects remain within the prediabetic range and are not superior to glibenclamide. Further research is needed to achieve normoglycemic reduction and consistent insulin effects under diabetic conditions.
- 16 July 2026
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
Open AccessFicus carica as an Antidiabetic Agent: Evidence from a Meta-analysis of In Vivo Studies
Recent evidence indicates that Ficus carica may exert glucose-lowering effects under diabetic conditions. However, reductions generally do not restore blood glucose to normal levels, raising questions about its reliability as an antidiabetic agent. This study aimed to systematically evaluate the glucose-lowering effects of F. carica in experimental diabetes models through meta-analysis, with additional assessments of dosage influence and comparison to glibenclamide. Relevant studies were retrieved from PubMed, Scopus, and Web of Science, including in vivo experiments on diabetic rats reporting blood glucose or insulin outcomes after F. carica intervention. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using meta-analysis based on leaf extract, dosage, and comparator treatment. F. carica leaf extract significantly reduced blood glucose compared to diabetic controls (SMD = –5.92; 95% CI [–8.13, –3.72]; p = .00001). Subgroup analyses demonstrated consistent effects at doses below 500 mg/kg BW (SMD = –8.11; 95% CI [–12.83, –3.39]; p = .0008) and above 400 mg/kg BW (SMD = –4.95; 95% CI [–7.49, –2.40]; p < .0001). Leaf extract showed no superior effect compared to glibenclamide (SMD = 2.10; 95% CI [0.91, 3.29]; p = .0006). A significant effect on insulin levels was observed in leaf extract (SMD = –3.65; 95% CI [–7.12, –0.18]; p = .04), though inconsistent effects were noted across other plant parts. In conclusion, F. carica demonstrates antidiabetic potential by reducing blood glucose in diabetic rats, but effects remain within the prediabetic range and are not superior to glibenclamide. Further research is needed to achieve normoglycemic reduction and consistent insulin effects under diabetic conditions.
- Open Access
In Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1
Breast cancer (BC) is one of the most common cancers in women and is a major cause of female cancer-related deaths. BC is a multifactorial disease caused by the dysregulation of many genes, raising the need to find novel drugs that function by targeting several signaling pathways. The antitumoral drug thymoquinone (TQ), found in black seed oil, has multitargeting properties against several signaling pathways. This study evaluated the inhibitory effects of TQ on the MCF7 and T47D human breast cancer cell lines and its antitumor activity against BC induced by a single oral dose (65 mg/kg) of 7,12-dimethylbenzanthracene (DMBA) in female rats. The therapeutic activity was evaluated in DMBA-treated rats who received oral TQ (50 mg/kg) three times weekly. TQ-treated MCF7 and T47D cells showed concentration-dependent inhibition of cell proliferation and induction of apoptosis. TQ also decreased the expression of DNA methyltransferase 1 (DNMT1) in both cancer cell types. In DMBA-treated animals, TQ inhibited the number of liver and kidney metastases. These effects were associated with a reduction in DNMT1 mRNA expression. These results indicate that TQ has protective effects against breast carcinogens through epigenetic mechanisms involving DNMT1 inhibition.
Open AccessIn Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1
Breast cancer (BC) is one of the most common cancers in women and is a major cause of female cancer-related deaths. BC is a multifactorial disease caused by the dysregulation of many genes, raising the need to find novel drugs that function by targeting several signaling pathways. The antitumoral drug thymoquinone (TQ), found in black seed oil, has multitargeting properties against several signaling pathways. This study evaluated the inhibitory effects of TQ on the MCF7 and T47D human breast cancer cell lines and its antitumor activity against BC induced by a single oral dose (65 mg/kg) of 7,12-dimethylbenzanthracene (DMBA) in female rats. The therapeutic activity was evaluated in DMBA-treated rats who received oral TQ (50 mg/kg) three times weekly. TQ-treated MCF7 and T47D cells showed concentration-dependent inhibition of cell proliferation and induction of apoptosis. TQ also decreased the expression of DNA methyltransferase 1 (DNMT1) in both cancer cell types. In DMBA-treated animals, TQ inhibited the number of liver and kidney metastases. These effects were associated with a reduction in DNMT1 mRNA expression. These results indicate that TQ has protective effects against breast carcinogens through epigenetic mechanisms involving DNMT1 inhibition.
- Open Access
- 27 January 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 320
A Comparative Study for Measuring Serum Ferritin Levels with Three Different Laboratory Methods: Enzyme-Linked Immunosorbent Assay versus Cobas e411 and Cobas Integra 400 Methods
Different laboratory methods are used to measure serum ferritin levels as a marker of iron status in the general population. This study aimed to compare serum ferritin levels using enzyme-linked immunosorbent assay (ELISA) versus immunochemiluminescence (Cobas e411) and immunoturbidimetric (Cobas Integra 400) methods in terms of sensitivity, specificity and accuracy, and whether they can be used interchangeably. A comparative cross-sectional study enrolled one hundred and six adult Yemeni patients (33 males and 73 females) aged 18–55 years, recruited from the dermatology and cosmetic center of Hadhramout Modern Hospital, Mukalla, Yemen. Serum ferritin levels were measured using ELISA, Cobas e411, and Cobas Integra 400 methods. For method comparison, a paired-sample t-test was used. For the consistency between the three methods, they were analyzed with regression and Pearson correlation coefficient. For determining accuracy, a receiver operating curve (ROC) was used. Bias error between the methods was determined through a Bland–Altman plot analysis. Our results did not show any significant statistical difference between ELISA and Cobas e411 (52.55 ± 7.4 µg/L vs. 52.58 ± 7.5 µg/L, p = 0.967), while there were significantly higher values from Cobas Integra 400 results than Cobas e411 (56.31 ± 7.8 µg/L vs. 52.58 ± 7.5 µg/L, p < 0.001) and ELISA (52.55 ± 7.4 µg/L vs. 56.31 ± 7.8 µg/L, p < 0.001). According to the correlation coefficient and linear regression analysis, a strong association between ELISA with Cobas e411 (r = 0.993, p < 0.001) and Cobas Integra 400 results (r = 0.994, p < 0.001) were revealed. For determining accuracy, Cobas e411 and Cobas Integra 400 results showed higher sensitivity (92.0%; 90.0%) and specificity (97.7%; 99.9%) respectively. Additionally, the Bland–Altman plot analysis showed a high agreement between the ELISA and Cobas e411 methods (bias: −0.035). In contrast, there was a low agreement between the ELISA and Cobas Integra 400 methods (bias: −3.75). Similarly, the agreement between Cobas e411 and Cobas Integra 400 methods was low (bias: −3.72). Serum ferritin levels were measured by Cobas e411, and Cobas Integra 400 methods were strongly correlated with the ELISA results, with higher sensitivity, specificity, and accuracy. However, further investigations with larger samples are required for improved accuracy and more precise results, and to determine whether they can be used interchangeably.
- 27 January 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (2) , 320
Open AccessA Comparative Study for Measuring Serum Ferritin Levels with Three Different Laboratory Methods: Enzyme-Linked Immunosorbent Assay versus Cobas e411 and Cobas Integra 400 Methods
Different laboratory methods are used to measure serum ferritin levels as a marker of iron status in the general population. This study aimed to compare serum ferritin levels using enzyme-linked immunosorbent assay (ELISA) versus immunochemiluminescence (Cobas e411) and immunoturbidimetric (Cobas Integra 400) methods in terms of sensitivity, specificity and accuracy, and whether they can be used interchangeably. A comparative cross-sectional study enrolled one hundred and six adult Yemeni patients (33 males and 73 females) aged 18–55 years, recruited from the dermatology and cosmetic center of Hadhramout Modern Hospital, Mukalla, Yemen. Serum ferritin levels were measured using ELISA, Cobas e411, and Cobas Integra 400 methods. For method comparison, a paired-sample t-test was used. For the consistency between the three methods, they were analyzed with regression and Pearson correlation coefficient. For determining accuracy, a receiver operating curve (ROC) was used. Bias error between the methods was determined through a Bland–Altman plot analysis. Our results did not show any significant statistical difference between ELISA and Cobas e411 (52.55 ± 7.4 µg/L vs. 52.58 ± 7.5 µg/L, p = 0.967), while there were significantly higher values from Cobas Integra 400 results than Cobas e411 (56.31 ± 7.8 µg/L vs. 52.58 ± 7.5 µg/L, p < 0.001) and ELISA (52.55 ± 7.4 µg/L vs. 56.31 ± 7.8 µg/L, p < 0.001). According to the correlation coefficient and linear regression analysis, a strong association between ELISA with Cobas e411 (r = 0.993, p < 0.001) and Cobas Integra 400 results (r = 0.994, p < 0.001) were revealed. For determining accuracy, Cobas e411 and Cobas Integra 400 results showed higher sensitivity (92.0%; 90.0%) and specificity (97.7%; 99.9%) respectively. Additionally, the Bland–Altman plot analysis showed a high agreement between the ELISA and Cobas e411 methods (bias: −0.035). In contrast, there was a low agreement between the ELISA and Cobas Integra 400 methods (bias: −3.75). Similarly, the agreement between Cobas e411 and Cobas Integra 400 methods was low (bias: −3.72). Serum ferritin levels were measured by Cobas e411, and Cobas Integra 400 methods were strongly correlated with the ELISA results, with higher sensitivity, specificity, and accuracy. However, further investigations with larger samples are required for improved accuracy and more precise results, and to determine whether they can be used interchangeably.
- Open Access
- 3 May 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 22 (1) , 1-15
Suppression of circulating AP001429.1 long non‑coding RNA in obese patients with breast cancer
Long non‑coding RNAs (lncRNAs), a type of cellular RNA, play a critical regulatory role in several physiological developments and pathological processes, such as tumorigenesis and tumor progression. Obesity is a risk factor for a number of serious health conditions, including breast cancer (BC). However, the underlying mechanisms behind the association between obesity and increased BC incidence and mortality remain unclear. Several studies have reported changes in lncRNA expression due to obesity and BC, independently encouraging further investigation of the relationship between the two in connection with lncRNAs. The present study was designed to first screen for the expression of 29 selected lncRNAs that showed a link to cancer or obesity in the blood of a selected cohort of 6 obese and 6 non‑obese patients with BC. The expression levels of significantly expressed lncRNAs, AP001429.1, PCAT6, P5549, P19461 and P3134, were further investigated in a larger cohort of 69 patients with BC (36 obese and 33 non‑obese), using reverse transcription‑quantitative polymerase chain reaction. Results showed not only that AP001429.1 remained significantly downregulated in the larger cohort (P=0.002), but also that it was associated with several clinicopathological characteristics, such as negative HER2 status, negative E‑cadherin expression, negative vascular invasion, negative margin invasion and LCIS. These findings suggest that obesity may have a role in inhibiting AP001429.1 expression, which may serve as a novel potential biomarker and therapeutic target for BC.
- 3 May 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 22 (1) , 1-15
Open AccessSuppression of circulating AP001429.1 long non‑coding RNA in obese patients with breast cancer
Long non‑coding RNAs (lncRNAs), a type of cellular RNA, play a critical regulatory role in several physiological developments and pathological processes, such as tumorigenesis and tumor progression. Obesity is a risk factor for a number of serious health conditions, including breast cancer (BC). However, the underlying mechanisms behind the association between obesity and increased BC incidence and mortality remain unclear. Several studies have reported changes in lncRNA expression due to obesity and BC, independently encouraging further investigation of the relationship between the two in connection with lncRNAs. The present study was designed to first screen for the expression of 29 selected lncRNAs that showed a link to cancer or obesity in the blood of a selected cohort of 6 obese and 6 non‑obese patients with BC. The expression levels of significantly expressed lncRNAs, AP001429.1, PCAT6, P5549, P19461 and P3134, were further investigated in a larger cohort of 69 patients with BC (36 obese and 33 non‑obese), using reverse transcription‑quantitative polymerase chain reaction. Results showed not only that AP001429.1 remained significantly downregulated in the larger cohort (P=0.002), but also that it was associated with several clinicopathological characteristics, such as negative HER2 status, negative E‑cadherin expression, negative vascular invasion, negative margin invasion and LCIS. These findings suggest that obesity may have a role in inhibiting AP001429.1 expression, which may serve as a novel potential biomarker and therapeutic target for BC.